The Visas Dividing MAGA World Help Power the U.S. Tech Industry
Mint Bangalore|January 02, 2025
Behind the uproar over the H-1B visa is a simple fact: America's tech industry is hooked on imported labor.
Paul Kiernan & Angel Au-Yeung

The program was at the center of a fight that broke out between President-elect Donald Trump's supporters over the holidays. Elon Musk and other tech executives defended H-1B visas as crucial to the success of U.S. businesses. Other stalwarts in the MAGA movement said tech companies should be forced to hire American workers.

Amazon.com, Google, and Tesla are among the biggest users of the visas, which let companies bring foreign workers to the U.S. on a temporary basis. The workers overwhelmingly come from India and fill jobs in such fields as software development, computer science, and engineering.

Created by Congress in 1990, the H-1B program is the main pathway to the U.S. for highly skilled foreign workers. Visa holders can eventually become eligible to apply for green cards, which would let them stay in the country indefinitely.

The program is vastly oversubscribed, with new visas capped at 85,000 a year. Companies file hundreds of thousands of petitions for the visas a year. A lottery system helps decide who gets in. Employees of universities and other nonprofits are generally exempt from the cap.

Esta historia es de la edición January 02, 2025 de Mint Bangalore.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición January 02, 2025 de Mint Bangalore.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE MINT BANGALOREVer todo
Mint Bangalore

Nvidia Shows New Chips, Inks Toyota Deal for Robotic Cars

Shares of Toyota, Nvidia's suppliers rise on optimism about the AI chip maker's prospects

time-read
3 minutos  |
January 08, 2025
Mint Bangalore

DIAL drops plea over Hindon ops expansion

Delhi International Airport Ltd (DIAL) on Tuesday withdrew its legal challenge against the Centre's decision to allow the Airports Authority of India (AAI) to operate scheduled commercial flights from the Indian Air Force Station in Hindon, Ghaziabad.

time-read
1 min  |
January 08, 2025
Mint Bangalore

Auto sales rise 9% in 2024 despite headwinds: Fada

Inventory build-up, delayed harvest payments, weak consumer sentiment weighed on demand in Dec

time-read
1 min  |
January 08, 2025
Mint Bangalore

Razorpay Charts Return to India; Eyes Expansion, IPO

Firm is likely to complete its reverse-flip in six months, with an IPO expected in two years

time-read
3 minutos  |
January 08, 2025
Mint Bangalore

Bank profits set to moderate in FY26 as bad assets rise

Ind-Ra sharply revised down its FY25 system credit growth estimate to 13-13.5% from 15% earlier

time-read
2 minutos  |
January 08, 2025
Mint Bangalore

Lloyds Metals shines on likely gains from acquisition, capex

Lloyds Metals & Energy Ltd's shares have gained about 15% so far in 2025 after the company's quarterly update and announcement of employee stock options (Esops) for its 6,000 workers.

time-read
1 min  |
January 08, 2025
Mint Bangalore

Another tough year for FMCG?

Feeling blue

time-read
2 minutos  |
January 08, 2025
Mint Bangalore

Your fancy, new ETF might be a little too fancy

Exchange-traded funds have mostly been great investments, but they are getting too complex for their own good

time-read
4 minutos  |
January 08, 2025
Mint Bangalore

Risks to economy escalating in 2025, cautions SBICAPS

Rising household debt, fluctuating FII flows among risks that threaten to amplify economic fragility: Report

time-read
1 min  |
January 08, 2025
Mint Bangalore

Intas Pharma bags another overseas company

Gujarat-based drug-maker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek, and Abu Dhabi Investment Authority (ADIA) as its investors, has signed a deal to acquire a biologic medication brand from US-based Coherus Biosciences.

time-read
1 min  |
January 08, 2025